Substituted aminomethyl isoxazoline derivatives useful as antimicrobials

Derives d'isoxazoline aminomethyle substitues utiles en tant qu'agents antimicrobiens

Abstract

L'invention concerne de nouveaux dérivés d'isoxazoline aminohétéroaromatique substitués représentés par la formule (I), dans laquelle R1 représente H, alkyle, cycloalkyle, alcoxy ou alkylamino: Y représente H, F ou CH3; W représente O ou S; le noyau P représente une fraction hétéroaromatique à 5 éléments comprenant un à trois atomes sélectionnés dans le groupe constitué d'atomes de soufre, d'azote et d'oxygène, cette fraction hétéroaromatique à 5 éléments pouvant en outre comprendre un naphtyle ou un benzène fusionné, une fraction hétéroaromatique à 6 éléments qui comprend au moins un atome d'azote, cette fraction hétéroaromatique à 6 éléments pouvant en outre comprendre un naphtyle ou un benzène fusionné ou une fraction hétéroaromatique à 5 éléments qui comprend de un à trois atomes sélectionnés dans le groupe constitué d'atomes de soufre, d'azote et d'oxygène; Q représente une fraction hétérocyclique à 4, 5, 6, 7 ou 9 éléments qui comprennent au moins un azote, un soufre et/ou un oxygène. Les composés selon l'invention possèdent une activité antimicrobienne élevée pour prévenir et traiter des maladies infectieuses.
The present invention provides novel substituted aminoheteroaromatic isoxazoline derivatives of formula (I), wherein R1 is H, alkyl, cycloalkyl, alkoxy, amino, or alkylamino; Y is H, F, or CH3; W is O, or S; Ring P is a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of sulfur, nitrogen and oxygen atoms, wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl, a 6-membered heteroaromatic moiety having at least one nitrogen atom, wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene, naphthyl or 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of sulfur, nitrogen and oxygen atoms; Q is a 4-, 5-, 6-, 7-, or 9-membered heterocyclic moiety containing one or more nitrogen, sulfur and/or oxygen. The compounds of the invention have high antimicrobial activity for preventing and treating infectious diseases.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (7)

    Publication numberPublication dateAssigneeTitle
    DE-2100242-A1July 15, 1971
    EP-0785200-A2July 23, 1997Bayer AgThienyl et furanyloxazolidinones pyridoannelées
    US-3769295-AOctober 30, 1973Ciba Geigy CorpNitrofuryl derivatives of 5-substituted isoxazolines
    US-4283403-AAugust 11, 1981Eli Lilly And CompanySubstituted isoxazolines for control of plant phytopathogens
    WO-9623788-A1August 08, 1996Pharmacia + Upjohn CompanyPhenyloxazolidinone substituee par un noyau heteroaromatique comme agent antimicrobien
    WO-9807708-A1February 26, 1998Pharmacia & Upjohn CompanyIsoxazoline derivatives useful as antimicrobials
    WO-9854161-A1December 03, 1998Pharmacia & Upjohn CompanyOxazolidinone antibacterial agents having a thiocarbonyl functionality

NO-Patent Citations (0)

    Title

Cited By (19)

    Publication numberPublication dateAssigneeTitle
    US-6617339-B1September 09, 2003Syngenta LimitedOxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
    US-7022705-B2April 04, 2006Astrazeneca AbIsoxazoline derivatives useful as antimicrobials
    US-7767677-B2August 03, 2010Xenon Pharmaceuticals Inc.Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
    US-7777036-B2August 17, 2010Xenon Pharmaceuticals Inc.Heterocyclic derivatives and their use as therapeutic agents
    US-7829712-B2November 09, 2010Xenon Pharmaceuticals Inc.Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
    US-7919496-B2April 05, 2011Xenon Pharmaceuticals Inc.Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
    US-7951805-B2May 31, 2011Xenon Pharmaceuticals Inc.Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
    US-8026360-B2September 27, 2011Xenon Pharmaceuticals Inc.Substituted pyridazines as stearoyl-CoA desaturase inhibitors
    US-8071603-B2December 06, 2011Xenon Pharmaceuticals Inc.Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
    US-8541457-B2September 24, 2013Xenon Pharmaceuticals Inc.Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
    US-8729079-B2May 20, 2014Endo Pharmaceuticals Inc.Pyrimido-pyridazinone compounds and methods of use thereof
    US-9382277-B2July 05, 2016Asana Biosciences, LlcPyrimido-pyridazinone compounds and methods of use thereof
    US-9656997-B2May 23, 2017Amgen Inc.Triazole agonists of the APJ receptor
    US-9656998-B2May 23, 2017Amgen Inc.Intermediates for preparing triazole agonists of the APJ receptor
    US-9751864-B2September 05, 2017Amgen Inc.Methods for preparing triazole agonists of the APJ receptor
    US-9845310-B2December 19, 2017Amgen Inc.Intermediates for preparing triazole agonists of the APJ receptor